BioNTech SE - ADR vs Bank of New York Mellon Corp — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while Bank of New York Mellon Corp trades at $161.02 (market cap $108.78B). The key difference: Bank of New York Mellon Corp is far larger — about 4.7× BioNTech SE - ADR's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | BNY | |
|---|---|---|
Market Cap | $23.31B | $108.78B |
Sector | Health | Financials |
52-Week High | $119.34 | $162.35 |
52-Week Low | $83.89 | $101.00 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 1.38% |
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →